The University of Southampton
University of Southampton Institutional Repository

A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial

A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial
A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial
This phase II trial describes the use of TIP chemotherapy (paclitaxel, ifosfamide and cisplatin) as salvage for patients with metastatic germ cell cancer (GCC) who have failed initial BEP (bleomycin, etoposide and cisplatin) chemotherapy. Patients with first relapse following BEP for metastatic GCC, confirmed by biopsy or sequentially rising markers, received four courses of TIP (paclitaxel 175 mg m?² day 1, followed on days 1-5 by ifosfamide 1 g m?² intravenously (i.v.) and cisplatin 20 mg² i.v.) at 3-weekly intervals. The primary outcome measure was response to TIP. In all, 51 patients were registered, of whom 43 were eligible for response assessment. Eight achieved complete remission (CR) and 18 a partial remission with negative markers (PR-ve); favourable response rate (FRR=CR+PR-ve) 60%, 95% CI (44-75%); survival at 1 year was 70% (56-84%) and failure-free survival 36% (22-50%). In the group of 26 patients meeting the 'good-risk' criteria described by the Memorial Hospital, the FRR was 73% (52-88%) compared with 41% (18-67%) for the 17 'poor-risk' patients. These results are inferior to those previously reported for TIP in a single-centre study when it was given more intensively, at higher dose and with growth factor support. Nonetheless, TIP as described here can cure a substantial proportion of patients.
cisplatin, ifosfamide, metastatic germ cell cancer, paclitaxel, salvage chemotherapy
0007-0920
178-184
Mead, G. M.
4af8e94c-c21e-46ad-9e88-f600773afffc
Cullen, M. H.
a6b15e4f-cd18-40e6-82f8-5c64cd1040d2
Huddart, R.
76d2b300-d66c-4b49-8bee-47755651a4a8
Harper, P.
93a9f992-d1de-4748-b77a-00917cf3e879
Rustin, G. J.
93439539-42f2-43e0-9dd8-97a9d509d38d
Cook, P. A.
20e73b23-1079-454d-b213-e43affa82f62
Stenning, S. P.
ca532844-c5f9-4d46-be58-58785ae63ed1
Mason, M.
e53b197a-e1a0-4fd1-8123-b5b64f47098f
Mead, G. M.
4af8e94c-c21e-46ad-9e88-f600773afffc
Cullen, M. H.
a6b15e4f-cd18-40e6-82f8-5c64cd1040d2
Huddart, R.
76d2b300-d66c-4b49-8bee-47755651a4a8
Harper, P.
93a9f992-d1de-4748-b77a-00917cf3e879
Rustin, G. J.
93439539-42f2-43e0-9dd8-97a9d509d38d
Cook, P. A.
20e73b23-1079-454d-b213-e43affa82f62
Stenning, S. P.
ca532844-c5f9-4d46-be58-58785ae63ed1
Mason, M.
e53b197a-e1a0-4fd1-8123-b5b64f47098f

Mead, G. M., Cullen, M. H., Huddart, R., Harper, P., Rustin, G. J., Cook, P. A., Stenning, S. P. and Mason, M. (2005) A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. British Journal of Cancer, 93 (2), 178-184. (doi:10.1038/sj.bjc.6602682).

Record type: Article

Abstract

This phase II trial describes the use of TIP chemotherapy (paclitaxel, ifosfamide and cisplatin) as salvage for patients with metastatic germ cell cancer (GCC) who have failed initial BEP (bleomycin, etoposide and cisplatin) chemotherapy. Patients with first relapse following BEP for metastatic GCC, confirmed by biopsy or sequentially rising markers, received four courses of TIP (paclitaxel 175 mg m?² day 1, followed on days 1-5 by ifosfamide 1 g m?² intravenously (i.v.) and cisplatin 20 mg² i.v.) at 3-weekly intervals. The primary outcome measure was response to TIP. In all, 51 patients were registered, of whom 43 were eligible for response assessment. Eight achieved complete remission (CR) and 18 a partial remission with negative markers (PR-ve); favourable response rate (FRR=CR+PR-ve) 60%, 95% CI (44-75%); survival at 1 year was 70% (56-84%) and failure-free survival 36% (22-50%). In the group of 26 patients meeting the 'good-risk' criteria described by the Memorial Hospital, the FRR was 73% (52-88%) compared with 41% (18-67%) for the 17 'poor-risk' patients. These results are inferior to those previously reported for TIP in a single-centre study when it was given more intensively, at higher dose and with growth factor support. Nonetheless, TIP as described here can cure a substantial proportion of patients.

This record has no associated files available for download.

More information

Published date: 2005
Keywords: cisplatin, ifosfamide, metastatic germ cell cancer, paclitaxel, salvage chemotherapy

Identifiers

Local EPrints ID: 26477
URI: http://eprints.soton.ac.uk/id/eprint/26477
ISSN: 0007-0920
PURE UUID: 0ea1a9b3-b0d4-45a1-96bd-ebe4e1df4155

Catalogue record

Date deposited: 21 Apr 2006
Last modified: 15 Mar 2024 07:11

Export record

Altmetrics

Contributors

Author: G. M. Mead
Author: M. H. Cullen
Author: R. Huddart
Author: P. Harper
Author: G. J. Rustin
Author: P. A. Cook
Author: S. P. Stenning
Author: M. Mason

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×